A new Phase 2b clinical trial will study the effectiveness of antiretroviral vaginal gels and oral tablets in preventing HIV infection in women.

The Vaginal and Oral Interventions to Control the Epidemic (VOICE) study will test the safety and efficacy of two different HIV prevention methods. The gel contains Viread (tenofovir), and the oral tablets contain Viread or Truvada (emtricitabine/tenofovir).

For the first time, participants will be able to apply the gel at any time throughout the day. This makes the gel easier to use and offers greater privacy than…

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), is conducting a Phase 2 clinical trial called HVTN 505. The study examines whether a particular two-part vaccine treatment can decrease the amount of virus in the body (viral load) in participants who later contract HIV. HIV-infected individuals with a lower viral load are more likely to remain healthier longer and less likely to spread the virus to other individuals.

The purpose of the study is to answer scientific questions that could…